On 19th and 20th October the University of Barcelona will receive about one hundred international experts on cell therapies applied to organ transplantation during the fourth meeting of the group Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT). he conference, in the Aula Magna of the Historic Building, will be opened by the researcher Josep M. Grinyó, professor of Medicine at the UB, head of the Nephrology Service and the Unity of Renal Transplantation of the University Hospital of Bellvitge and member of the Bellvitge Biological Research Institute IDIBELL.
MiSOT is a non-profit organization which brings together research groups and institutes interested in doing research and implementing the cell therapy with mesenchymal stem cells in the treatment of the solid organ transplantation rejection. Currently, we are making the first steps towards these clinical and medical applications, at the same time that the first clinical studies with transplanted patients are being developed in order to evaluate their security and effectiveness. In the conference some initial results of these clinical studies will be presented and some examples about the new action mechanisms discovered will be gone through.
The research on mesenchymal stem cells in transplantations generates scientific knowledge and, at the same time, it can lead to some guidelines to minimise immunosuppressants with an attenuation of the comorbidity associated with these therapies. In addition, getting the graft acceptance by reducing the immunosuppressant mechanisms improves the clinical tolerance to these treatments and reduces their cost.
MiSOT group, composed by members from all over Europe and from the United States, was created in 2008. From its creation, three occasions of this conference have been organized, one in Regensburg (Germany), another in Rotterdam (Netherlands), and last year’s one in Lovaina (Belgium). These conferences gave birth to two international publications in the journal Transplantation.
Some of the speakers are: Giussepe Remuzzi, director of the Department of Nephrology and Dialysis of the Ospedali Riuniti in Bergamo; Antonello Pileggi, lecturer at the University of Miami; Marlies Reinders and Cess van Kooten, clinical and experimental nephrologists in the Leiden University Medical Center; Albert Sánchez Fueyo, member of the Unidad de Transplantamente Hepàtic at the Hospital Clínic-IDIBAPS; Josep M. Aran, head of the group of Molecular Genetics of IDIBELL; Robert Deans, vice president of Regenerative Medicine at Athersys Inc (Cleverland, United States); Bernard Mahon, immunologist at the University of Maynooth (Ireland); Ramon Farré, head of the IDIBAPS group on Respiratory Biophysics and Bioengineering; Antonio Uccelli, head of the Neuroimmunology service at the University of Geneva; Martin Hoogduijn, head of the research group on mesenchymal stem cells at the University Medical Center Rotterdam; and Marc Dahlke and Elke Eggenhofer, who lead research groups on transplantations and hepatic ischemia at the University Hospital Regensburg. Moreover, the researcher Josep M. Grinyó is a member of the scientific committee Marcel•la Franquesa, a postdoctoral researcher at the University Medical Center Rotterdam.
If you want to attend the conference, enrolment is still opened. The enrolment rate is of 150 € (100 € if you are a student) and it includes the attendance to the conference and the dinner, on 19th October in the Moritz bar.